|Bid||23.88 x 1200|
|Ask||24.50 x 1100|
|Day's Range||22.65 - 24.37|
|52 Week Range||9.74 - 27.82|
|Beta (5Y Monthly)||2.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2020 - Feb 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.00|
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK™ (tazemetostat) for the Treatment of FL
One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) Baudax Bio Inc (NASDAQ: BXRX ) Mesoblast limited (NASDAQ: ...
Epizyme (EPZM) gets a significant boost with the approval of Tazverik (tazemetostat) for the treatment of metastatic or locally advanced epithelioid sarcoma.
The TAZVERIK drug has been approved, particularly for the treatment of patients above the age of 16, who have metastatic or locally advanced epithelioid sarcoma that cannot be completely removed with surgery. The clinical benefit of the drug still needs to be verified in a confirmatory trial for the FDA's continued approval, as is usually required in cases where the federal agency grants accelerated approvals based on preliminary trials. Epizyme said that it is already performing a confirmatory trial that assesses the effects of a combination of TAXVERIK and chemotherapy drug Doxorubicin against a combination of the latter with a placebo.
The FDA has approved the drug Tazverik to treat metastatic or locally advanced epitheliod sarcoma, a rare and aggressive form of soft tissue cancer.
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.
Benzinga Pro's Stocks To Watch For Thursday Co-Diagnostics (CODX) - Shares were up 175+% in pre-market action following a company press release which highlighted Co-Diagnostics is designing a test for ...
The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.
Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. The drug's label expansion programs also look promising.
Biotech news flow remained light last week, although there were some notable developments such as FDA panel reviews of opioid pain drugs, a few clinical data readouts, presentations and updates at the ...
Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.
Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.
Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma.